DD285613A5 - Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern - Google Patents

Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern Download PDF

Info

Publication number: DD285613A5
Authority: DD; German Democratic Republic
Prior art keywords: mol; concentration; mmol; reactivation; guanidine hydrochloride
Prior art date: 1988-10-17

Application number

DD89333621A

Other languages

German (de)

English (en)

Inventor

Rainer Rudolph

Johannes Buchner

Helmut Lenz

Original Assignee

��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-17

Filing date

1989-10-16

Publication date

1990-12-19

1989-10-16 Application filed by ��@��@��k�� filed Critical ��@��@��k��

1990-12-19 Publication of DD285613A5 publication Critical patent/DD285613A5/de

Links

230000004913 activation Effects 0.000 title abstract description 9
108090000623 proteins and genes Proteins 0.000 claims abstract description 53
102000004169 proteins and genes Human genes 0.000 claims abstract description 50
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims abstract description 30
229960000789 guanidine hydrochloride Drugs 0.000 claims abstract description 25
230000007420 reactivation Effects 0.000 claims abstract description 23
239000000872 buffer Substances 0.000 claims abstract description 18
238000000502 dialysis Methods 0.000 claims abstract description 15
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 13
239000004202 carbamide Substances 0.000 claims abstract description 8
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 57
235000018102 proteins Nutrition 0.000 claims description 48
238000000034 method Methods 0.000 claims description 34
229960003180 glutathione Drugs 0.000 claims description 28
108010053070 Glutathione Disulfide Proteins 0.000 claims description 25
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 25
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 17
238000005063 solubilization Methods 0.000 claims description 16
230000007928 solubilization Effects 0.000 claims description 16
239000003398 denaturant Substances 0.000 claims description 11
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims description 10
239000000243 solution Substances 0.000 claims description 10
150000001875 compounds Chemical class 0.000 claims description 8
239000007983 Tris buffer Substances 0.000 claims description 6
239000003638 chemical reducing agent Substances 0.000 claims description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
239000004475 Arginine Substances 0.000 claims description 5
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
229940098773 bovine serum albumin Drugs 0.000 claims description 5
108010024636 Glutathione Proteins 0.000 claims description 4
230000003213 activating effect Effects 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
230000029087 digestion Effects 0.000 claims description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical group SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 3
102000016943 Muramidase Human genes 0.000 claims description 3
108010014251 Muramidase Proteins 0.000 claims description 3
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
229960003121 arginine Drugs 0.000 claims description 3
150000002019 disulfides Chemical class 0.000 claims description 3
229960000274 lysozyme Drugs 0.000 claims description 3
239000004325 lysozyme Substances 0.000 claims description 3
235000010335 lysozyme Nutrition 0.000 claims description 3
230000001590 oxidative effect Effects 0.000 claims description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims description 2
229960003589 arginine hydrochloride Drugs 0.000 claims description 2
239000000470 constituent Substances 0.000 claims description 2
235000018417 cysteine Nutrition 0.000 claims description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims description 2
230000007935 neutral effect Effects 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
238000002604 ultrasonography Methods 0.000 claims description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
239000012062 aqueous buffer Substances 0.000 claims 1
241000894006 Bacteria Species 0.000 abstract description 9
238000004153 renaturation Methods 0.000 description 33
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 13
241000588724 Escherichia coli Species 0.000 description 13
210000004027 cell Anatomy 0.000 description 12
210000003000 inclusion body Anatomy 0.000 description 12
239000012634 fragment Substances 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 9
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000001994 activation Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
229960004198 guanidine Drugs 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
239000008188 pellet Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000001514 detection method Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
238000010405 reoxidation reaction Methods 0.000 description 6
NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000004925 denaturation Methods 0.000 description 5
230000036425 denaturation Effects 0.000 description 5
102000004420 Creatine Kinase Human genes 0.000 description 4
108010042126 Creatine kinase Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
241001494479 Pecora Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108010044467 Isoenzymes Proteins 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
229930064664 L-arginine Natural products 0.000 description 3
235000014852 L-arginine Nutrition 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000013459 approach Methods 0.000 description 3
235000009697 arginine Nutrition 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000003196 chaotropic effect Effects 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
-1 B. 0.2 mol / 1 Chemical compound 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
108010054278 Lac Repressors Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
241001672648 Vieira Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000003774 sulfhydryl reagent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Saccharide Compounds (AREA)

DD89333621A 1988-10-17 1989-10-16 Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern DD285613A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3835350A DE3835350A1 (de)	1988-10-17	1988-10-17	Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern

Publications (1)

Publication Number	Publication Date
DD285613A5 true DD285613A5 (de)	1990-12-19

Family

ID=6365312

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD89333621A DD285613A5 (de)	1988-10-17	1989-10-16	Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern

Country Status (12)

Country	Link
US (1)	US5077392A (da)
EP (1)	EP0364926B1 (da)
JP (1)	JPH0793879B2 (da)
KR (1)	KR920010873B1 (da)
AT (1)	ATE101650T1 (da)
AU (1)	AU609645B2 (da)
CA (1)	CA2000604C (da)
DD (1)	DD285613A5 (da)
DE (2)	DE3835350A1 (da)
DK (1)	DK175439B1 (da)
ES (1)	ES2061876T3 (da)
IL (1)	IL92012A (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5453363A (en) *	1985-10-23	1995-09-26	Boehringer Mannheim Gmbh	Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5676947A (en) *	1989-02-07	1997-10-14	Boehringer Manneheim Gmbh	Method for treating thromboembolic conditions using thrombolytically active proteins
DE4037196A1 (de) *	1990-11-22	1992-05-27	Boehringer Mannheim Gmbh	Verfahren zur reaktivierung von denaturiertem protein
DE4105480A1 (de) *	1991-02-21	1992-08-27	Boehringer Mannheim Gmbh	Verbesserte aktivierung von rekombinanten proteinen
AU3812993A (en) *	1992-03-24	1993-10-21	Synergen, Inc.	Refolding and purification of insulin-like growth factor I
KR100310739B1 (ko) *	1993-02-04	2002-05-30	알란 스코브	단백질재생을위한개선된방법
JP4019432B2 (ja) *	1995-12-21	2007-12-12	味の素株式会社	ヒトアクチビンａのリフォールディング方法
AU2660397A (en) *	1996-04-05	1997-10-29	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) *	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
KR20100068498A (ko)	1997-08-15	2010-06-23	츄가이 세이야꾸 가부시키가이샤	항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제
US6489450B2 (en) *	1998-07-09	2002-12-03	University Technology Corporation	High pressure refolding of protein aggregates and inclusion bodies
EP1077263A1 (de) *	1999-07-29	2001-02-21	F.Hoffmann-La Roche Ag	Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
AU7053500A (en) *	1999-09-15	2001-04-17	Eli Lilly And Company	Chymotrypsin-free trypsin
US6808902B1 (en) *	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002062827A2 (en)	2000-10-31	2002-08-15	The Regents Of The University Of Colorado, A Body Corporate	Improved protein disaggregation and refolding using high pressure
DE10105912A1 (de) *	2001-02-09	2002-08-14	Roche Diagnostics Gmbh	Rekombinante Proteinase K
DE102005033250A1 (de)	2005-07-15	2007-01-18	Bioceuticals Arzneimittel Ag	Verfahren zur Reinigung von G-CSF
US20080032343A1 (en) *	2005-12-22	2008-02-07	Genentech, Inc.	Recombinant Production of Heparin Binding Proteins
DE202006020194U1 (de)	2006-03-01	2007-12-06	Bioceuticals Arzneimittel Ag	G-CSF-Flüssigformulierung
SG162834A1 (en)	2006-07-14	2010-07-29	Genentech Inc	Refolding of recombinant proteins
EP2059523A2 (en) *	2006-09-15	2009-05-20	Barofold, Inc.	High pressure treatment of proteins for reduced immunogenicity
WO2011113601A1 (en)	2010-03-17	2011-09-22	Biogenerix Ag	Method for obtaining biologically active recombinant human g-csf
HUP1200171A1 (hu)	2012-03-19	2013-09-30	Richter Gedeon Nyrt	Módszerek polipeptidek elõállítására
EP2831089A1 (en) *	2012-03-30	2015-02-04	Krishnan, Archana Rajesh	Process for renaturation of polypeptides
WO2014128726A2 (en) *	2013-02-22	2014-08-28	Biogenomics Limited	Process for high efficiency refolding of recombinant proteins
WO2014167574A1 (en) *	2013-03-22	2014-10-16	Biogenomics Limited	Process for isolation and stabilisation of key intermediates for high efficiency refolding of recombinant proteins
US10457716B2 (en)	2014-08-06	2019-10-29	University Of Notre Dame Du Lac	Protein folding and methods of using same
CN110643595A (zh) *	2019-10-21	2020-01-03	黑龙江精益检测有限公司	一种对化学修饰后磁性固定化pla1再活化的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR79124B (da) *	1982-12-22	1984-10-02	Genentech Inc
US4620948A (en) *	1982-12-22	1986-11-04	Genentech, Inc.	Purification and activity assurance of precipitated heterologous proteins
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4634586A (en) *	1984-05-21	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Reagent and method for radioimaging leukocytes
ES8800957A1 (es) *	1985-02-22	1987-12-01	Monsanto Co	Un metodo para la solubilizacion y renaturalizacion de proteina somatotropina
US4929444A (en) *	1985-05-28	1990-05-29	Burroughs Wellcome Co.	Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) *	1985-07-29	1986-10-22	Smithkline Beckman Corp	Pharmaceutical dosage unit
DE3537708A1 (de) *	1985-10-23	1987-04-23	Boehringer Mannheim Gmbh	Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4766205A (en) *	1985-11-13	1988-08-23	Beatrice Companies, Inc.	Method for isolation of recombinant polypeptides in biologically active forms
FR2594845B1 (fr) *	1986-02-21	1989-12-01	Genetica	Preparation par voie microbiologique de l'activateur tissulaire humain du plasminogene (t-pa) et conversion de l'enzyme ainsi obtenue en sa forme active
DE3611817A1 (de) *	1986-04-08	1987-10-15	Boehringer Mannheim Gmbh	Verfahren zur renaturierung von proteinen

1988
- 1988-10-17 DE DE3835350A patent/DE3835350A1/de not_active Withdrawn
1989
- 1989-10-13 CA CA002000604A patent/CA2000604C/en not_active Expired - Lifetime
- 1989-10-16 ES ES89119181T patent/ES2061876T3/es not_active Expired - Lifetime
- 1989-10-16 EP EP89119181A patent/EP0364926B1/de not_active Expired - Lifetime
- 1989-10-16 AT AT89119181T patent/ATE101650T1/de not_active IP Right Cessation
- 1989-10-16 DD DD89333621A patent/DD285613A5/de not_active IP Right Cessation
- 1989-10-16 DE DE89119181T patent/DE58906984D1/de not_active Expired - Lifetime
- 1989-10-16 AU AU42931/89A patent/AU609645B2/en not_active Expired
- 1989-10-17 IL IL9201289A patent/IL92012A/en not_active IP Right Cessation
- 1989-10-17 DK DK198905159A patent/DK175439B1/da not_active IP Right Cessation
- 1989-10-17 KR KR1019890014951A patent/KR920010873B1/ko not_active Expired
- 1989-10-17 US US07/422,948 patent/US5077392A/en not_active Expired - Lifetime
- 1989-10-17 JP JP1268298A patent/JPH0793879B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IL92012A0 (en)	1990-07-12
KR900006515A (ko)	1990-05-08
IL92012A (en)	1994-12-29
AU4293189A (en)	1990-04-26
EP0364926B1 (de)	1994-02-16
DK175439B1 (da)	2004-10-18
US5077392A (en)	1991-12-31
DE58906984D1 (de)	1994-03-24
JPH02227090A (ja)	1990-09-10
DE3835350A1 (de)	1990-04-19
CA2000604A1 (en)	1990-04-17
AU609645B2 (en)	1991-05-02
CA2000604C (en)	1999-07-06
KR920010873B1 (ko)	1992-12-19
JPH0793879B2 (ja)	1995-10-11
EP0364926A2 (de)	1990-04-25
EP0364926A3 (de)	1991-05-02
ES2061876T3 (es)	1994-12-16
DK515989D0 (da)	1989-10-17
DK515989A (da)	1990-04-18
ATE101650T1 (de)	1994-03-15

Legal Events

Date	Code	Title	Description
1996-09-26	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0364926B1 (de)	1994-02-16	Aktivierung von gentechnologisch hergestellten, in Prokaryonten exprimierten Antikörpern
EP0393725B1 (de)	1995-12-13	Verfahren zur Aktivierung von gentechnolgish hergestellten, heterologen, Disulfidbrücken aufweisenden eukaryontischen Proteinen nach Expression in Prokaryonten
EP1394179B1 (de)	2006-07-26	Verfahren zur Herstellung von Erythropoietin frei von tierischen Proteinen
DE3852140T2 (de)	1995-04-06	Produktion von Proteinen in aktiven Formen.
EP0904355B1 (de)	2004-03-03	Verfahren zur aktivierung von denaturiertem protein
DE69101486T2 (de)	1994-08-04	Verfahren zur reinigung rekombinanter polypeptide.
DE4201181A1 (de)	1993-07-22	Verfahren zur stabilisierung von proteinen
DE3881895T2 (de)	1993-12-02	Verfahren zur Reinigung von Vitamin-K-abhängigen Blutgerinnungsfaktoren.
PAPADOPOULOS	1991	Identification and purification of a human Sertoli cell-secreted protein (hSCSP-80) stimulating Leydig cell steroid biosynthesis
DE3486023T2 (de)	1993-06-24	Verfahren zur herstellung von urokinase zymogen.
Waldman et al.	1983	Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase
DE69631906T2 (de)	2005-01-20	Verfahren zur herstellung von richtig gefaltetem, biologisch aktivem, rekombinantem protein
US20040235089A1 (en)	2004-11-25	Process for solubilization of recombinant proteins expressed as inclusion body
EP0599344B1 (de)	1997-09-24	Verfahren zur Stabilisierung von Proteinen
WO1990003388A1 (de)	1990-04-05	Präparat von in prokaryonten exprimiertem plasminogenaktivator
WO2011131736A1 (de)	2011-10-27	Verfahren zur herstellung von rekombinantem thrombin
DE19930676A1 (de)	2001-01-18	Verfahren zur Stabilisierung von Proteinen in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
EP0367161A2 (de)	1990-05-09	Verfahren zur selektiven Spaltung von Fusionsproteinen
JPH04144695A (ja)	1992-05-19	分泌蛋白質のリフォールディング法
CZ280848B6 (cs)	1996-04-17	Způsob aktivace genetickou technologií získaných heterologních bílkovin s obsahem disulfidových můstků eukaryotického původu po expresi v prokaryotických organismech